370 related articles for article (PubMed ID: 28374319)
1. Application of a PK-PD Modeling and Simulation-Based Strategy for Clinical Translation of Antibody-Drug Conjugates: a Case Study with Trastuzumab Emtansine (T-DM1).
Singh AP; Shah DK
AAPS J; 2017 Jul; 19(4):1054-1070. PubMed ID: 28374319
[TBL] [Abstract][Full Text] [Related]
2. Development of a Translational Physiologically Based Pharmacokinetic Model for Antibody-Drug Conjugates: a Case Study with T-DM1.
Khot A; Tibbitts J; Rock D; Shah DK
AAPS J; 2017 Nov; 19(6):1715-1734. PubMed ID: 28808917
[TBL] [Abstract][Full Text] [Related]
3. On translation of antibody drug conjugates efficacy from mouse experimental tumors to the clinic: a PK/PD approach.
Haddish-Berhane N; Shah DK; Ma D; Leal M; Gerber HP; Sapra P; Barton HA; Betts AM
J Pharmacokinet Pharmacodyn; 2013 Oct; 40(5):557-71. PubMed ID: 23933716
[TBL] [Abstract][Full Text] [Related]
4. Mechanistic pharmacokinetic/pharmacodynamic modeling of in vivo tumor uptake, catabolism, and tumor response of trastuzumab maytansinoid conjugates.
Wada R; Erickson HK; Lewis Phillips GD; Provenzano CA; Leipold DD; Mai E; Johnson H; Tibbitts J
Cancer Chemother Pharmacol; 2014 Nov; 74(5):969-80. PubMed ID: 25186956
[TBL] [Abstract][Full Text] [Related]
5. Preclinical and clinical pharmacokinetic/pharmacodynamic considerations for antibody-drug conjugates.
Sapra P; Betts A; Boni J
Expert Rev Clin Pharmacol; 2013 Sep; 6(5):541-55. PubMed ID: 23978126
[TBL] [Abstract][Full Text] [Related]
6. A mechanistic pharmacokinetic model elucidating the disposition of trastuzumab emtansine (T-DM1), an antibody-drug conjugate (ADC) for treatment of metastatic breast cancer.
Bender B; Leipold DD; Xu K; Shen BQ; Tibbitts J; Friberg LE
AAPS J; 2014 Sep; 16(5):994-1008. PubMed ID: 24917179
[TBL] [Abstract][Full Text] [Related]
7. A Mechanism-Based PK/PD Model for Hematological Toxicities Induced by Antibody-Drug Conjugates.
Ait-Oudhia S; Zhang W; Mager DE
AAPS J; 2017 Sep; 19(5):1436-1448. PubMed ID: 28646408
[TBL] [Abstract][Full Text] [Related]
8. Evolution of Antibody-Drug Conjugate Tumor Disposition Model to Predict Preclinical Tumor Pharmacokinetics of Trastuzumab-Emtansine (T-DM1).
Singh AP; Maass KF; Betts AM; Wittrup KD; Kulkarni C; King LE; Khot A; Shah DK
AAPS J; 2016 Jul; 18(4):861-75. PubMed ID: 27029797
[TBL] [Abstract][Full Text] [Related]
9. Use of translational modeling and simulation for quantitative comparison of PF-06804103, a new generation HER2 ADC, with Trastuzumab-DM1.
Betts A; Clark T; Jasper P; Tolsma J; van der Graaf PH; Graziani EI; Rosfjord E; Sung M; Ma D; Barletta F
J Pharmacokinet Pharmacodyn; 2020 Oct; 47(5):513-526. PubMed ID: 32710210
[TBL] [Abstract][Full Text] [Related]
10. Population pharmacokinetics of trastuzumab emtansine in previously treated patients with HER2-positive advanced gastric cancer (AGC).
Chen SC; Kagedal M; Gao Y; Wang B; Harle-Yge ML; Girish S; Jin J; Li C
Cancer Chemother Pharmacol; 2017 Dec; 80(6):1147-1159. PubMed ID: 29043411
[TBL] [Abstract][Full Text] [Related]
11. A population pharmacokinetic/pharmacodynamic model of thrombocytopenia characterizing the effect of trastuzumab emtansine (T-DM1) on platelet counts in patients with HER2-positive metastatic breast cancer.
Bender BC; Schaedeli-Stark F; Koch R; Joshi A; Chu YW; Rugo H; Krop IE; Girish S; Friberg LE; Gupta M
Cancer Chemother Pharmacol; 2012 Oct; 70(4):591-601. PubMed ID: 22886072
[TBL] [Abstract][Full Text] [Related]
12. Effects of Drug-Antibody Ratio on Pharmacokinetics, Biodistribution, Efficacy, and Tolerability of Antibody-Maytansinoid Conjugates.
Sun X; Ponte JF; Yoder NC; Laleau R; Coccia J; Lanieri L; Qiu Q; Wu R; Hong E; Bogalhas M; Wang L; Dong L; Setiady Y; Maloney EK; Ab O; Zhang X; Pinkas J; Keating TA; Chari R; Erickson HK; Lambert JM
Bioconjug Chem; 2017 May; 28(5):1371-1381. PubMed ID: 28388844
[TBL] [Abstract][Full Text] [Related]
13. The effect of different linkers on target cell catabolism and pharmacokinetics/pharmacodynamics of trastuzumab maytansinoid conjugates.
Erickson HK; Lewis Phillips GD; Leipold DD; Provenzano CA; Mai E; Johnson HA; Gunter B; Audette CA; Gupta M; Pinkas J; Tibbitts J
Mol Cancer Ther; 2012 May; 11(5):1133-42. PubMed ID: 22408268
[TBL] [Abstract][Full Text] [Related]
14. Improved Tumor Penetration and Single-Cell Targeting of Antibody-Drug Conjugates Increases Anticancer Efficacy and Host Survival.
Cilliers C; Menezes B; Nessler I; Linderman J; Thurber GM
Cancer Res; 2018 Feb; 78(3):758-768. PubMed ID: 29217763
[TBL] [Abstract][Full Text] [Related]
15. Antibody Coadministration as a Strategy to Overcome Binding-Site Barrier for ADCs: a Quantitative Investigation.
Singh AP; Guo L; Verma A; Wong GG; Thurber GM; Shah DK
AAPS J; 2020 Jan; 22(2):28. PubMed ID: 31938899
[TBL] [Abstract][Full Text] [Related]
16. Preclinical Evaluation of
Hartimath SV; Alizadeh E; Solomon VR; Chekol R; Bernhard W; Hill W; Parada AC; Barreto K; Geyer CR; Fonge H
J Nucl Med; 2019 Aug; 60(8):1103-1110. PubMed ID: 30655327
[TBL] [Abstract][Full Text] [Related]
17. Evolution of the Systems Pharmacokinetics-Pharmacodynamics Model for Antibody-Drug Conjugates to Characterize Tumor Heterogeneity and
Singh AP; Seigel GM; Guo L; Verma A; Wong GG; Cheng HP; Shah DK
J Pharmacol Exp Ther; 2020 Jul; 374(1):184-199. PubMed ID: 32273304
[TBL] [Abstract][Full Text] [Related]
18. Antibody-Drug Conjugates: Pharmacokinetic/Pharmacodynamic Modeling, Preclinical Characterization, Clinical Studies, and Lessons Learned.
Hedrich WD; Fandy TE; Ashour HM; Wang H; Hassan HE
Clin Pharmacokinet; 2018 Jun; 57(6):687-703. PubMed ID: 29188435
[TBL] [Abstract][Full Text] [Related]
19. Exposure-response analyses of trastuzumab emtansine in patients with HER2-positive advanced breast cancer previously treated with trastuzumab and a taxane.
Li C; Wang B; Chen SC; Wada R; Lu D; Wang X; Polhamus D; French J; Vadhavkar S; Strasak A; Smitt M; Joshi A; Samant M; Quartino A; Jin J; Girish S
Cancer Chemother Pharmacol; 2017 Dec; 80(6):1079-1090. PubMed ID: 29022084
[TBL] [Abstract][Full Text] [Related]
20. Modeling the efficacy of trastuzumab-DM1, an antibody drug conjugate, in mice.
Jumbe NL; Xin Y; Leipold DD; Crocker L; Dugger D; Mai E; Sliwkowski MX; Fielder PJ; Tibbitts J
J Pharmacokinet Pharmacodyn; 2010 Jun; 37(3):221-42. PubMed ID: 20424896
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]